Lucintel Forecasts $1,226 Billion Market for Global Pharmaceutical Industry Stakeholders by 2018


   January 1 2013

The global pharmaceutical industry revenue is forecasted to reach an estimated $1,226.0 billion by 2018, with good growth over the next five years (2013-2018). The industry is expected to register growth led by aging population, changing lifestyles, hectic daily activities, unhealthy eating habits, increasing incidence of chronic diseases across the entire global population providing growth opportunities for the industry players.

Lucintel, a leading global Management Consulting and market research firm, has conducted a competitive analysis of the industry and presents its findings in “Global Pharmaceutical Industry 2013-2018: Trend, Profit, and Forecast Analysis.” The industry is engaged in discovery, development, manufacture, and marketing of prescription drugs. Industry products include ethical drugs and consumer healthcare but animal healthcare drugs are not included.

The global pharmaceutical market faces major challenge from increasing investment and strict regulation. Changing lifestyles and the fast socio-demographic shift due to urbanization in both developed and growth markets globally are expected drive the demand. The ability to create new technology and innovative drugs is a key driver for success in this market.

North America is projected to lead the pharmaceutical industry. Vaccine industry is expected to record the highest growth during the forecast period. ROW industry is expected to witness the highest growth during 2013-2018. Government initiatives in Brazil to encourage drugs industries by providing free pricing policies and special financial investment options will attract the industry players. APAC holds good growth potential for the future.

This study provides an overview of the global pharmaceutical industry by tracking 13 market segments of that industry in four geographic regions. Thus, a total of 52 segments of the global pharmaceutical industry are tracked. The report studies manufacturers of bone, respiratory, immunology and dermatology, cardiovascular, diabetes & obesity, urinary/kidney diseases, gastrointestinal, neurosciences, infectious diseases, ophthalmology, oncology, women’s health/ endocrine, vaccines, consumer health/OTC, and others providing a five-year (2007-2012) annual trend analysis that highlights market size, profit and cost structure for NA, Europe, APAC, and ROW. The report also provides a forecast, addressing market opportunities for next five years (2013-2018) for each of these regions.

For a detailed table of contents and pricing information on this timely, insightful report, contact Lucintel at +1-972-636-5056 or via email at helpdesk@lucintel.com. Lucintel provides cutting-edge decision support services that facilitate critical decisions with greater speed, insight, and cost efficiency. To learn more, visit www.lucintel.com.

Lucintel Corporate Customers

Market Entry, M & A, Opportunity Screening,...

Private Equity Customers

Buy Side Services (target screening, due diligence, ..)

Market Research Reports

Aerospace & Defense [44]
Chemical [100]
Composites & Advanced Materials [99]
Construction & Industrial [40]
Consumer and Retail [78]
Economic Analysis [86]
Energy & Utility [68]
Finance & Services [10]
Healthcare [23]
Media & Entertainment [16]
Metals & Mining [16]
Technology & Telecommunication [44]
Transportation [75]

Customer Quotes

"With more than 20 years experience in the industry, this is the first time we have come across such an extensive market analysis for our industry." Ven Cote, CEO, ZCL

"The insights we gained from Lucintel work helped with our business plan…a wonderful professional job…" Mike Jackson, Stahlin

"The report from Lucintel is useful not only for business planners, but also for the technology officers wanting to create a roadmap …" Dr. Giulio Ranzo, Booz Allen

"The information is so comprehensive, it has allowed us to identify & focus our business development efforts. It saved months of leg-work." Bill Barz, L&L Products

"We bought Lucintel report because it is the best report about our industry…a complete and appropriate analysis." Cesare Andrenacci, Ferretti

Quick Query

Partnership between Jushi USA and Gray Construction ...
Armor Express Awarded Five-Year ID/IQ Hard Armor Contract from U.S. Customs and Border Protection...
Hyundai Files Patent for CFRP Front End...
Velocity Composites Signs Long Term Agreement ...
Johns Manville's Starrov 853 for LFT Reinforcements is Available in Americas and Europe ...

Follow us on